| metastatic/adv melanoma (mML) | ||||
| mML - NA - all population | mML - NA - PDL1 positive | mML - L2 - all population | mML - L2 - BRAF mutant | |
| pembrolizumab based treatment | ||||
| pembrolizumab alone | KEYNOTE 054 ... | KEYNOTE 054 ... | ||
| pembrolizumab (10mg/kg) | KEYNOTE-006 ... KEYNOTE-002 ... | |||
| pembrolizumab (10mg/kg) 2 weeks | KEYNOTE-006 ... | |||
| pembrolizumab (2mg/kg) | KEYNOTE-002 ... | |||
| pembrolizumab plus SoC | KEYNOTE-022 | |||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
